Originally published as JCO Early Release 10.1200/JCO.2004.05.065 on August 2 2004

This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schrag, D. Articles by Somerfield, M. R. Search for Related Content PubMed PubMed Citation Articles by Schrag, D. Articles by Somerfield, M. R. Social Bookmarking                            What's this?

American Society of Clinical Oncology Technology Assessment: Chemotherapy Sensitivity and Resistance Assays

From the American Society of Clinical Oncology, Alexandria, VA

Address reprint requests to American Society of Clinical Oncology, Cancer Policy and Clinical Affairs, 1900 Duke St, Suite 200, Alexandria, VA 22314; e-mail: guidelines{at}asco.org

PURPOSE: To develop a technology assessment of chemotherapy sensitivity and resistance assays in order to define the role of these tests in routine oncology practice.

METHODS: The American Society of Clinical Oncology (ASCO) established a Working Group to develop the technology assessment. The Working Group collaborated with the Blue Cross and Blue Shield Association (BCBSA) Technology Evaluation Center. The Working Group developed independent criteria for selecting articles for inclusion in the ASCO assessment, and developed a structured data abstraction tool to facilitate review of selected manuscripts. One Working Group member and an ASCO staff member independently reviewed the 1,139 abstracts identified by the BCBSA comprehensive literature search, and by an updated literature search performed by ASCO using the BCBSA search strategy (1966 to January 2004). Of the 12 articles included in this technology assessment, eight were identified by the original BCBSA systematic review, one was provided by industry, and three were identified by the ASCO updated literature review.

RESULTS: Review of the literature does not identify any CSRAs for which the evidence base is sufficient to support use in oncology practice.

RECOMMENDATIONS: The use of chemotherapy sensitivity and resistance assays to select chemotherapeutic agents for individual patients is not recommended outside of the clinical trial setting. Oncologists should make chemotherapy treatment recommendations on the basis of published reports of clinical trials and a patient's health status and treatment preferences. Because the in vitro analytic strategy has potential importance, participation in clinical trials evaluating these technologies remains a priority.

Disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. H. Lyman ASCO Clinical Practice Guidelines: Past, Present and Future J. Oncol. Pract, September 1, 2008; 4(5): 236 - 237. [Full Text] [PDF]

				B. Singh and D. G. Pfister Individualized Treatment Selection in Patients With Head and Neck Cancer: Do Molecular Markers Meet the Challenge? J. Clin. Oncol., July 1, 2008; 26(19): 3114 - 3116. [Full Text] [PDF]

				J. Nieto, M. L. Grossbard, and P. Kozuch Metastatic Pancreatic Cancer 2008: Is the Glass Less Empty? Oncologist, May 1, 2008; 13(5): 562 - 576. [Abstract] [Full Text] [PDF]

				E. Azambuja, V. Durbecq, D. D. Rosa, M. Colozza, D. Larsimont, M. Piccart-Gebhart, and F. Cardoso HER-2 overexpression/amplification and its interaction with taxane-based therapy in breast cancer Ann. Onc., February 1, 2008; 19(2): 223 - 232. [Abstract] [Full Text] [PDF]

				G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, and L. C. Hartmann Current Management Strategies for Ovarian Cancer Mayo Clin. Proc., June 1, 2007; 82(6): 751 - 770. [Abstract] [Full Text] [PDF]

				T. A. d'Amato, R. J. Landreneau, W. Ricketts, W. Huang, R. Parker, E. Mechetner, I.-R. Yu, and J. D. Luketich Chemotherapy resistance and oncogene expression in non-small cell lung cancer J. Thorac. Cardiovasc. Surg., February 1, 2007; 133(2): 352 - 363. [Abstract] [Full Text] [PDF]

				B. Rubio-Viqueira, H. Mezzadra, M. E. Nielsen, A. Jimeno, X. Zhang, C. Iacobuzio-Donahue, A. Maitra, M. Hidalgo, and S. Altiok Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays Mol. Cancer Ther., February 1, 2007; 6(2): 515 - 523. [Abstract] [Full Text] [PDF]

				P. Hwu, A. Y. Bedikian, and E. A. Grimm Challenges of chemosensitivity testing. Clin. Cancer Res., September 15, 2006; 12(18): 5258 - 5259. [Full Text] [PDF]

				S. Ugurel, D. Schadendorf, C. Pfohler, K. Neuber, A. Thoelke, J. Ulrich, A. Hauschild, K. Spieth, M. Kaatz, W. Rittgen, et al. In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group. Clin. Cancer Res., September 15, 2006; 12(18): 5454 - 5463. [Abstract] [Full Text] [PDF]

				A. Jimeno, P. Kulesza, E. Kincaid, N. Bouaroud, A. Chan, A. Forastiere, J. Brahmer, D. P. Clark, and M. Hidalgo C-fos Assessment as a Marker of Anti-Epidermal Growth Factor Receptor Effect Cancer Res., February 15, 2006; 66(4): 2385 - 2390. [Abstract] [Full Text] [PDF]

				D. G. Pfister and J. A. Ridge Induction Chemotherapy for Larynx Preservation: Patient Selection or Therapeutic Effect? J. Clin. Oncol., February 1, 2006; 24(4): 540 - 543. [Full Text] [PDF]

				M. Markman Chemosensitivity and Chemoresistance Testing J. Clin. Oncol., October 10, 2005; 23(29): 7363 - 7364. [Full Text] [PDF]

				R. Nagourney Chemosensitivity and Resistance Assays: A Systematic Review? J. Clin. Oncol., May 20, 2005; 23(15): 3640 - 3641. [Full Text] [PDF]

				J. P. Fruehauf and D. S. Alberts In Vitro Drug Resistance Versus Chemosensitivity: Two Sides of Different Coins J. Clin. Oncol., May 20, 2005; 23(15): 3641 - 3643. [Full Text] [PDF]

				H. S. Wieand Chemotherapy Sensitivity and Response Assays: Are the ASCO Guidelines for Clinical Trial Design Too Restrictive? J. Clin. Oncol., May 20, 2005; 23(15): 3643 - 3644. [Full Text] [PDF]

				M. Castro Resisting a Fundamentalist Policy J. Clin. Oncol., May 20, 2005; 23(15): 3645 - 3646. [Full Text] [PDF]